Tirzepatide Injection: What the Research Shows

The short version

A tirzepatide injection is a once-weekly subcutaneous injection — a short needle into the skin of the abdomen, thigh, or upper arm. It is not an IV drip, not an intramuscular shot, and not a pill. The 'once weekly' is made possible by the drug's design: a chemical modification on the peptide (a fatty-diacid arm) makes it bind to albumin in the blood, which dramatically slows how fast the body clears it. The resulting half-life is about 5 days — long enough that one injection a week maintains a steady blood level. The dose starts low (2.5 mg) and increases slowly over months to the maintenance dose (up to 15 mg), because the GI side effects are largely dose-escalation events: they peak during each step-up and then diminish. The subcutaneous injection route was the only route studied in the clinical trial programme; there is no approved oral form.

Tirzepatide injection: route and administration

Subcutaneous injection (SC injection) is the only approved route for tirzepatide — both in the clinical trial programme (SURPASS and SURMOUNT) and in the FDA prescribing information ^[1][16]. SC injection means delivery into the subcutaneous fat layer just under the skin, using a short fine needle, not into muscle or vein.

Approved injection sites per the label: abdomen (stomach area), thigh, or upper arm. Injection sites should be rotated to avoid repeated tissue trauma at a single site, which is associated with injection site reactions (redness, bruising, lumps) documented in post-market safety reports ^[16].

Once-weekly timing: injections can be given on any day of the week, at any time of day, with or without food. The critical constraint is the once-weekly interval — not the specific day or time.

Pharmacokinetics: what the ~5-day half-life means

The elimination half-life of tirzepatide is approximately 5 days, established in the Phase 1 pharmacokinetic programme ^[1]. This half-life is the product of the molecule's design: the C20 fatty-diacid arm (eicosanedioic acid) attached to the GIP-backbone peptide confers high albumin affinity. Albumin is the most abundant protein in plasma — binding to it dramatically slows renal filtration and degradation, extending the drug's time in circulation.

For once-weekly dosing, a ~5-day half-life means the drug accumulates to steady state over approximately 4 weeks of dosing (roughly four to five half-lives). For discontinuation: five half-lives means roughly 25 days for most of the drug to clear after the last dose. This has implications for the perioperative setting (see below) and for anticipating when GI effects might resolve after stopping.

Gastric emptying and perioperative considerations

One consequence of the tirzepatide injection mechanism is delayed gastric emptying — slowing of the rate at which the stomach passes its contents into the small intestine. This is a GLP-1 receptor-mediated effect that also occurs with selective GLP-1 agonists; in tirzepatide the effect is transient and attenuates with continued dosing ^[23].

Because of the ~5-day half-life and slowed gastric and small-intestinal motility, retained gastric contents have been documented at upper-GI endoscopy in tirzepatide users, even after standard pre-procedure fasting. This raises a theoretical concern for pulmonary aspiration (inhaling stomach contents) under sedation or general anaesthesia, though documented aspiration events are rare ^[22].

Reviewers have proposed strategies including prolonged fasting intervals, point-of-care gastric ultrasound before procedures, or prokinetic agents in the peri-procedural window ^[22][23]. The GI tolerability picture and what community members report is on the effects page.

Tirzepatide injection schedule from the trial programmes

In the SURPASS and SURMOUNT phase 3 programmes, the dose-escalation schedule used was ^[4][8][16]:

• 2.5 mg once weekly (weeks 1-4)
• 5 mg once weekly (weeks 5-8)
• 7.5 mg once weekly (weeks 9-12)
• 10 mg once weekly (weeks 13-16)
• 12.5 mg once weekly (weeks 17-20)
• 15 mg once weekly (maintenance, or 10 mg for participants not tolerating 15 mg)

The 20-week escalation period was designed specifically to manage gastrointestinal tolerability. In SURMOUNT-1, gastrointestinal adverse events were most common during dose escalation and were mostly mild to moderate ^[4]. The phase 3 trial schedule matches the FDA label's approved dose-escalation guidance.

For what is tirzepatide — the mechanism and receptor pharmacology — see the dedicated explainer page. Tirzepatide references lists all trial citations.